Financing Agreement Signed

March 9, 2025

A loan agreement has been signed between Reykjavík Energy and the Council of Europe Development Bank (CEB), as announced to the stock exchange on September 30, 2024, following the bank’s approval.
The loan amount is EUR 75 million and will be used to develop heating and water utilities, including enhancing the resilience of utility systems against natural hazards.

Contact:
Snorri Hafsteinn Þorkelsson
CFO
[email protected]

Hot this week

Topics

Popular Categories

News RoomFeatured CompaniesVideos

Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

FTI Consulting Further Bolsters Asia Business Transformation Practice with Senior Appointments

Financing Agreement Signed

Methanex Provides Update on Geismar Operations

FTI Consulting Further Bolsters Asia Business Transformation Practice with Senior Appointments

Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

Kaldalón hf.: Annual General Meeting 3 April 2025

Topics

Methanex Provides Update on Geismar Operations

FTI Consulting Further Bolsters Asia Business Transformation Practice with Senior Appointments

Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

Kaldalón hf.: Annual General Meeting 3 April 2025

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Changes in the Supervisory Board and Management Board of subsidiary

Holding(s) in Company

Related Articles

Methanex Provides Update on Geismar Operations

FTI Consulting Further Bolsters Asia Business Transformation Practice with Senior Appointments

Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

Kaldalón hf.: Annual General Meeting 3 April 2025

Company

Headlines

Methanex Provides Update on Geismar Operations

FTI Consulting Further Bolsters Asia Business Transformation Practice with Senior Appointments

Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

Newsletter